Alnylam Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Mpeg La, L.l.c.

Alnylam Europe Ag

Novartis Ag

The Scripps Research Institute

Mina Therapeutics Limited

Giuliani International Limited

Mayo Foundation for Medical Education and Research

Hans-Peter Vornlocher

Philipp Hadwiger

Pamela Tan

Anke Geick

Ingo Roehl

Stefan Limmer

Birgit Bramlage

Roland Kreutzer

David A Bumcrot

Juergen Soutschek

Sayda Mahgoub Elbashir

Dinah Wen-Yee Sah

Gino Van Heeke

Emma Hickman

Henry Luke Danahay

Olaf Heidenreich

Akin Akinc

Jonathan Miles Brown

Matthias John

Kristin K H Neuman

Muthiah Manoharan

Kallanthottathil G Rajeev

Tracy Stage Zimmermann

John M Maraganore

Rainer Constien

Maria Frank-Kamenetsky

James E Dahlman

William Balch

Andrea Forst

Antonin De Fougerolles

Kevin Fitzgerald

Markus Hossbach

Pål Sætrom

Dinah Sah

Hans E Huber

Matthew J Farrer

Monika Krampert

Detlef Schuppan

Heiko Van Der Kuip

John Benson

Claudia Woppmann

Andreas Steinbrecher

Andreas Wagner

Gerhard Giegerich

Ingo Kleiter

Robert Habib

Markus Horn

Endre Bakken Stovner

Rainer Apfel

Matthias Ocker

Christoph Herold

Christina Lorenz

Demetrius Maraganore

The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.

Multimeric oligonucleotides having decreased kidney clearance

Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.

Defined multi-conjugates oligonucleotides

Defined multi-conjugate oligonucleotides

The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

RNAi inhibition of alpha-ENaC expression

The invention relates to saRNA targeting a C/EBP&#x3b1; transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.

C/EBP alpha saRNA compositions and methods of use

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.

Compositions and methods for inhibiting expression of factor V

The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.

Glycoconjugates of RNA interference agents

The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.

RNAi modulation of ApoB and uses thereof

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.

Compositions and methods for inhibiting expression of Eg5 gene

This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.

Nuclease resistant double-stranded ribonucleic acid

Growing community of inventors

Bayreuth, Germany

Hans-Peter Vornlocher